Kojin is a biotechnology company with special emphasis in cell state and ferroptosis biology to create novel therapies and cures. Founded by Benjamin Cravatt, Stephanie Dougan, Stuart L. Schreiber, and Vasanthi Viswanathan in 2020, Kojin Therapeutics is backed by investors that include Binney Street Capital, Polaris Partners, AbbVie, Eventide Asset Management, and Cathay Capital and is headquartered in Cambridge.